Published in final edited form as:

J Dtsch Dermatol Ges. 2018 February ; 16(2): 196–198. doi:10.1111/ddg.13411.

Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma.

Kyle T. Amber¹, Manuel Valdebran¹, Yuxin Lu², Sebastien De Feraudy¹, and Kenneth G. Linden¹

¹Department of Dermatology, University of California Irvine, Irvine, California, USA.

²Department of Pathology, University of California Irvine Medical Center, Orange, California, USA.

To the editors,

An 82-year-old female presented with a pruritic bullous dermatitis to the bilateral pretibial legs of 5 months duration. Her medical history was significant for metastatic melanoma Stage IV (T1N2M1b) for which she had been placed on pembrolizumab 6 months prior to the onset of her pretibial rash due to the development of widespread nodal involvement and pulmonary nodules. She received 9 doses of 2mg/kg at approximately 3 week intervals, with a significant decrease in the size of her lung nodules prior to developing her pretibial rash. The plaque had begun as a faint pruritic erythematous patch, for which the patient tried numerous therapies including topical neomycin and other over-the-counter topical antibiotics. Thus, contact dermatitis was originally suspected, and the patient was instructed to discontinue all therapies. Her dermatitis progressed, with subsequent development of tense bullae and erosions at the site of previous bullae on an erythematous plaque limited to her pretibial legs (Figure 1).

Histopathology of an intact vesicle demonstrated a subepidermal split with numerous eosinophils (Figure 2a). Perilesional direct immunofluorescence demonstrated strong binding of C3 and IgG at the basement membrane zone (Figure 2b). Indirect immunofluorescence demonstrated IgG deposition at a titer of 1:1280 on monkey esophagus substrate, with a positive epidermal pattern at a titer of 1:2560 on human split-skin substrate. Testing for IgA was negative. ELISA for BP180 was positive at 46 units, but BP230 was negative at 2 units, with a reference of less than 9 for both tests. In combination, these findings supported the diagnosis of localized pretibial bullous pemphigoid, a grade 1 adverse event to pembrolizumab. The patient was subsequently placed on topical clobetasol to the affected areas twice daily while continuing on pembrolizumab for her metastatic melanoma. She developed a transient generalization of her bullous pemphigoid which responded to a 2-week prednisone taper. Thereafter, she had limited pretibial involvement which was controlled with clobetasol at 6-months follow-up.

Address correspondence to: Dr. Kyle T. Amber, Department of Dermatology, University of California Irvine Health, 118 Med Surg 1, Irvine, CA 92697, P 305-609-2110; F: 949-824-7454, KAmber@UCI.edu.

COI disclosure: The authors have no potential conflicts of interest to disclose

Bullous pemphigoid is an autoimmune subepidermal blistering disorder characterized by subepidermal bullae formation, deposition of immunoglobulins or complement components at the dermoepidermal junction (DEJ), and autoantibodies against the BP180 and/or BP230. BP presents typically in elder individuals with a phase of pruritus followed by widespread blister formation. Less common variants have been described and include vesicular pemphigoid, pemphigoid vegetans, localized pretibial pemphigoid, and pemphigoid nodularis [1]. Our patient presented with localized pretibial pemphigoid, a rare variant of BP, reported in approximately 1% of BP patients [2]. While clinically distinct, it is indistinguishable serologically and histopathological from the widespread variant BP [3, 4].

PD-1 inhibitor induced BP has been described previously in several patients [5–7]. It is thought that the result of blocking the PD-1/PD-L1 axis leads to a breakdown of tolerance and a development of a T cell response against BP 180 [6, 8]. On the other hand, Naidoo et al propose the coexistence of a humoral response through a B-cell germinal center stimulation by PD1⁺ follicular helper T cells [6].

Recent studies have suggested a potential relation between melanoma and BP, though this has yet to be confirmed in large population studies. Investigators have demonstrated the expression of BP180 in melanoma cells but not in normal melanocytes [9]. Likewise, several cases have demonstrated a parallel with clinical course of BP and melanoma [10]. Moreover, the HLA-DQB1*03:01 allele which has been associated to BP has been found in higher frequencies in melanoma patients [11]. Thus, patients receiving PD-1 inhibitors for melanoma may be both exposed to BP180 from their melanoma, as well as experience T-cell dysregulation leading to functional autoimmunity against the BP180 protein [12].

We herein present, to our knowledge, the first reported case of localized bullous pemphigoid arising in a patient receiving PD-1 inhibitors. This case further supports the systemic nature of localized pretibial BP. It remains unclear why some patients develop this localized form rather than generalized, despite the systemic circulation of autoantibodies.

Acknowledgments

Funding: This work was unfunded

References:

1. Schmidt E, della Torre R, Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. *Immunol Allergy Clin North Am* 2012; 32: 217–32, v. [PubMed: 22560135]
2. Chang YT, Liu HN, Wong CK. Bullous pemphigoid--a report of 86 cases from Taiwan. *Clin Exp Dermatol* 1996; 21: 20–2. [PubMed: 8689763]
3. Kawahara Y, Matsumura K, Hashimoto T, Nishikawa T. Immunoblot analysis of autoantigens in localized pemphigoid and pemphigoid nodularis. *Acta Derm Venereol* 1997; 77: 187–90. [PubMed: 9188867]
4. Muramatsu T, Iida T, Shirai T. Antibasement membrane zone antibodies in localized pretibial pemphigoid. *Int J Dermatol* 1991; 30: 422–4. [PubMed: 1894407]
5. Jour G, Glitz IC, Ellis RM, Torres-Cabala CA, Tetzlaff MT, Li JY, Nagarajan P, Huen A, Aung PP, Ivan D, Drucker CR, Prieto VG, Rapini RP, Patel A, Curry JL. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. *J Cutan Pathol* 2016; 43: 688–96. [PubMed: 27086658]

6. Naidoo J, Schindler K, Querfeld C, Busam K, Cunningham J, Page DB, Postow MA, Weinstein A, Lucas AS, Ciccolini KT, Quigley EA, Lesokhin AM, Paik PK, Chaft JE, Segal NH, D'Angelo SP, Dickson MA, Wolchok JD, Lacouture ME. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. *Cancer Immunol Res* 2016; 4: 383–9. [PubMed: 26928461]
7. Schmidgen MI, Butsch F, Schadmand-Fischer S, Steinbrink K, Grabbe S, Weidenthaler-Barth B, Loquai C. Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic melanoma. *J Dtsch Dermatol Ges* 2017; 15: 742–45.
8. Kahler KC, Hassel JC, Heinzerling L, Loquai C, Mossner R, Ugurel S, Zimmer L, Gutzmer R. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. *J Dtsch Dermatol Ges* 2016; 14: 662–81.
9. Krenacs T, Kiszner G, Stelkovics E, Balla P, Teleki I, Nemeth I, Varga E, Korom I, Barbai T, Plotar V, Timar J, Raso E. Collagen XVII is expressed in malignant but not in benign melanocytic tumors and it can mediate antibody induced melanoma apoptosis. *Histochem Cell Biol* 2012; 138: 653–67. [PubMed: 22688676]
10. Amber KT, Panganiban CM, Korta D, Feraudy S, Kelly KM, Grando SA. A case report of bullous pemphigoid associated with a melanoma and review of the literature. *Melanoma Res* 2017; 27: 65–67. [PubMed: 27759577]
11. Lee JE, Reveille JD, Ross MI, Platsoucas CD. HLA-DQB1*0301 association with increased cutaneous melanoma risk. *Int J Cancer* 1994; 59: 510–3. [PubMed: 7960221]
12. Amber KT, Zikry J, Hertl M. A multi-hit hypothesis of bullous pemphigoid and associated neurological disease: Is HLA-DQB1*03:01, a potential link between immune privileged antigen exposure and epitope spreading? *Hla* 2017.

Figure 1. Tense bullae and erosions at the site of previous bullae on an erythematous plaque limited to the pretibial legs on presentation (a), and follow up (b,c). Arrows point to few residual tense bullae

Figure 2.

A) hematoxylin and eosin stained tissue demonstrating subepidermal clefting with numerous eosinophils (10x) and C) confirmation of linear IgG along the basement membrane by direct immunofluorescence.